JNJ Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
16 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 23.04
- PEG ratio
- 3.07
- P/B
- 8.07
- P/S (TTM)
- 6.62
- EV/EBITDA
- 25.55
Profitability & growth
- ROE (TTM)
- 20.0%
- Operating margin
- 25.7%
- Revenue growth YoY
- 5.9%
- Dividend yield
- 1.9%
- Beta
- 0.21
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Johnson & Johnson
Company profileJohnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ
- Fiscal year end
- December
- Latest quarter
- Sep 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
